S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   165.03 (-1.20%)
MSFT   399.52 (-1.17%)
META   484.01 (-3.55%)
GOOGL   154.03 (-1.27%)
AMZN   174.96 (-2.38%)
TSLA   149.16 (-0.51%)
NVDA   804.06 (-5.04%)
AMD   149.40 (-3.66%)
NIO   3.83 (-4.25%)
BABA   68.85 (-0.04%)
T   16.36 (+0.18%)
F   12.09 (+0.25%)
MU   107.39 (-4.06%)
GE   149.19 (-2.45%)
CGC   8.09 (+3.32%)
DIS   112.13 (-0.27%)
AMC   3.24 (+10.96%)
PFE   25.81 (+1.65%)
PYPL   62.16 (+0.10%)
XOM   120.07 (+1.31%)
S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   165.03 (-1.20%)
MSFT   399.52 (-1.17%)
META   484.01 (-3.55%)
GOOGL   154.03 (-1.27%)
AMZN   174.96 (-2.38%)
TSLA   149.16 (-0.51%)
NVDA   804.06 (-5.04%)
AMD   149.40 (-3.66%)
NIO   3.83 (-4.25%)
BABA   68.85 (-0.04%)
T   16.36 (+0.18%)
F   12.09 (+0.25%)
MU   107.39 (-4.06%)
GE   149.19 (-2.45%)
CGC   8.09 (+3.32%)
DIS   112.13 (-0.27%)
AMC   3.24 (+10.96%)
PFE   25.81 (+1.65%)
PYPL   62.16 (+0.10%)
XOM   120.07 (+1.31%)
S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   165.03 (-1.20%)
MSFT   399.52 (-1.17%)
META   484.01 (-3.55%)
GOOGL   154.03 (-1.27%)
AMZN   174.96 (-2.38%)
TSLA   149.16 (-0.51%)
NVDA   804.06 (-5.04%)
AMD   149.40 (-3.66%)
NIO   3.83 (-4.25%)
BABA   68.85 (-0.04%)
T   16.36 (+0.18%)
F   12.09 (+0.25%)
MU   107.39 (-4.06%)
GE   149.19 (-2.45%)
CGC   8.09 (+3.32%)
DIS   112.13 (-0.27%)
AMC   3.24 (+10.96%)
PFE   25.81 (+1.65%)
PYPL   62.16 (+0.10%)
XOM   120.07 (+1.31%)
S&P 500   4,989.32 (-0.44%)
DOW   38,028.74 (+0.67%)
QQQ   416.96 (-1.52%)
AAPL   165.03 (-1.20%)
MSFT   399.52 (-1.17%)
META   484.01 (-3.55%)
GOOGL   154.03 (-1.27%)
AMZN   174.96 (-2.38%)
TSLA   149.16 (-0.51%)
NVDA   804.06 (-5.04%)
AMD   149.40 (-3.66%)
NIO   3.83 (-4.25%)
BABA   68.85 (-0.04%)
T   16.36 (+0.18%)
F   12.09 (+0.25%)
MU   107.39 (-4.06%)
GE   149.19 (-2.45%)
CGC   8.09 (+3.32%)
DIS   112.13 (-0.27%)
AMC   3.24 (+10.96%)
PFE   25.81 (+1.65%)
PYPL   62.16 (+0.10%)
XOM   120.07 (+1.31%)
NASDAQ:PODD

Insulet (PODD) Stock Price, News & Analysis

$163.47
-1.26 (-0.76%)
(As of 01:34 PM ET)
Today's Range
$162.11
$167.10
50-Day Range
$163.25
$197.14
52-Week Range
$125.82
$335.91
Volume
253,091 shs
Average Volume
866,395 shs
Market Capitalization
$11.45 billion
P/E Ratio
56.18
Dividend Yield
N/A
Price Target
$243.21

Insulet MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
49.6% Upside
$243.21 Price Target
Short Interest
Healthy
4.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.20
Upright™ Environmental Score
News Sentiment
1.34mentions of Insulet in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1.89 M Sold Last Quarter
Proj. Earnings Growth
25.65%
From $3.08 to $3.87 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.69 out of 5 stars

Medical Sector

61st out of 918 stocks

Medical Devices Industry

1st out of 3 stocks

PODD stock logo

About Insulet Stock (NASDAQ:PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

PODD Stock Price History

PODD Stock News Headlines

7 Stable Stocks for 50% Returns by Early 2025
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Guru Fundamental Report for PODD
Insulet Names Ana Maria Chadwick CFO, Effective April 22
Here’s Why Insulet (PODD) Detracted in Q4
PODD Apr 2024 135.000 call
PODD Apr 2024 165.000 call
PODD Apr 2024 190.000 put
PODD Jan 2025 180.000 call
See More Headlines
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/19/2024
Next Earnings (Confirmed)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:PODD
CUSIP
45784P10
Employees
3,000
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$243.21
High Stock Price Target
$330.00
Low Stock Price Target
$184.00
Potential Upside/Downside
+47.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
15 Analysts

Profitability

Net Income
$206.30 million
Pretax Margin
12.65%

Debt

Sales & Book Value

Annual Sales
$1.70 billion
Cash Flow
$3.62 per share
Book Value
$10.49 per share

Miscellaneous

Free Float
69,392,000
Market Cap
$11.53 billion
Optionable
Optionable
Beta
0.98

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

PODD Stock Analysis - Frequently Asked Questions

Should I buy or sell Insulet stock right now?

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PODD shares.
View PODD analyst ratings
or view top-rated stocks.

What is Insulet's stock price target for 2024?

15 equities research analysts have issued twelve-month price objectives for Insulet's stock. Their PODD share price targets range from $184.00 to $330.00. On average, they anticipate the company's stock price to reach $243.21 in the next year. This suggests a possible upside of 49.6% from the stock's current price.
View analysts price targets for PODD
or view top-rated stocks among Wall Street analysts.

How have PODD shares performed in 2024?

Insulet's stock was trading at $216.98 on January 1st, 2024. Since then, PODD stock has decreased by 25.1% and is now trading at $162.59.
View the best growth stocks for 2024 here
.

When is Insulet's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our PODD earnings forecast
.

How can I listen to Insulet's earnings call?

Insulet will be holding an earnings conference call on Thursday, May 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings data on Thursday, February, 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.73. The medical instruments supplier earned $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. Insulet had a net margin of 12.16% and a trailing twelve-month return on equity of 32.19%. Insulet's revenue was up 37.9% compared to the same quarter last year. During the same period last year, the business posted $0.55 EPS.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its first quarter 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $419.0 million-$429.7 million, compared to the consensus revenue estimate of $442.5 million.

What is Shacey Petrovic's approval rating as Insulet's CEO?

61 employees have rated Insulet Chief Executive Officer Shacey Petrovic on Glassdoor.com. Shacey Petrovic has an approval rating of 55% among the company's employees. This puts Shacey Petrovic in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Block (SQ), Walt Disney (DIS), Salesforce (CRM), Roku (ROKU) and Trade Desk (TTD).

Who are Insulet's major shareholders?

Insulet's stock is owned by a variety of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.43%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), Portman Square Capital LLP (0.00%), Congress Asset Management Co. MA (0.06%), Banque Cantonale Vaudoise (0.01%) and Diversified Trust Co (0.01%). Insiders that own company stock include Bret Christensen, Charles Alpuche, Dan Manea, James Hollingshead, John A Fallon, Luciana Borio, Michael P Spears, Prem Singh, Sally Crawford, Shacey Petrovic and Wayde D Mcmillan.
View institutional ownership trends
.

How do I buy shares of Insulet?

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PODD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners